The stroke management market is set gain significant traction by 2027 owing to the steadily rising geriatric population across the world. Additionally, the growing incidences of cardiovascular diseases is also expected to augment market outlook.

Recent studies have shown that people that have recovered from Covid-19 are more likely to develop various cardiovascular ailments. This has led to an increase in the number of patients requiring intensive medical attention when it comes to stroke management.

Consequently, this growing prevalence of cardiovascular diseases has prompted medical enterprises around the world to develop enhanced equipment for diagnosis and therapy as well as medicines for treatment, which has boosted market expansion.

Prominent industry players are implementing lucrative strategies to gain a competitive edge in the rapidly evolving market. For instance, in September 2021, Abbott, a global healthcare company, announced the acquisition of a leading medical devices manufacturer, Walk Vascular, LLC. The company is responsible for developing minimally invasive mechanical systems to remove peripheral blood clots, called peripheral thrombectomy systems. The acquisition has enabled Abbott to expand its product offering and prepare itself for a wider market reach.

To cite another instance, in November 2020, Penumbra, Inc., a leading healthcare company specializing in innovative therapies, inked a partnership with RapidAI, a leading company that offers advanced imaging for strokes. According to the agreement, both the enterprises have developed efficient diagnosis and treatment procedures for pulmonary embolism (PE), which is an acute condition that causes formation of blood clots in the lungs.

The stroke management market has been bifurcated on the basis of product, type, end-use, and region.

In terms of type, the market has further been categorized into hemorrhagic, transient ischemic attack (TIA), ischemic, and others. The ischemic sub segment is projected to witness considerable growth over the review period, due to the increasing mortality rate associated with ischemic stroke caused by the formation of blood clot, which disrupts blood supply to the brain.

Based on product, the market has been divided into diagnostic devices (carotid ultrasound, computed tomography (CT) scan, cerebral angiography, magnetic resonance imaging (MRI), electrocardiography, and others) and therapeutic devices (flow diverters, stent retriever, embolic coils, surgical clips, aspiration catheters, and others).

The electrocardiography diagnostic devices segment is slated to observe lucrative growth by 2027, owing to prevalent demand for electrocardiogram, which is used to detect abnormal heartbeats and diagnosis for chest pain. In addition, increasing technological advancements in the development of convenient product solutions, is likely to foster segmental growth.

With respect to end-use, the market has been segmented into diagnostic centers, hospitals, ambulatory surgery centers, and others. The hospital sub segment is foreseen to showcase lucrative growth over the assessment period.

From a regional reference frame, the MEA segment is slated to register notable gains. The growing need to cater to an increasing disease burden within the region through the expansion of the healthcare services will offer unprecedented growth opportunities to the market players.